Pharmaceuticals & Healthcare Industrial & Manufacturing

DPR & CMA Data on Dextrose monohydrate, liquid glucose

Project Overview

Dextrose monohydrate, commonly referred to as liquid glucose, is a simple sugar derived from corn or other starch sources. It is primarily used in the pharmaceutical industry, as well as in food and beverage manufacturing, due to its ability to provide quick energy and stabilize formulations. Its versatility allows it to be incorporated into various products, including oral rehydration solutions, intravenous solutions, and nutritional supplements. The compound has a high solubility, making it suitable for both solid and liquid formulations, thereby increasing its applicability. The increasing demand for parenteral nutrition in hospitals and the growing trend of health and wellness products are driving the market for dextrose monohydrate. Additionally, the rise of sports nutrition supplements and functional foods is creating new opportunities for liquid glucose products. Regulatory approvals and quality certifications also underpin its acceptance and usage in various markets globally, enhancing its market presence. Furthermore, dextrose is often used as a sweetening agent and to enhance the palatability of various formulations, contributing to market growth. As consumers shift towards convenient health solutions, the demand for liquid glucose is projected to increase, making it an attractive investment in the pharmaceutical and health sectors.

Market Potential

  • Rising demand for parenteral nutrition in healthcare settings.
  • Increasing use of dextrose in sports and nutrition supplements.
  • Growing trend towards functional foods and beverages.
  • Expansion of the pharmaceutical sector with intravenous therapies.
  • Potential for use in biodegradable packaging and bioengineering.

SWOT Analysis

Strengths

  • High solubility and excellent stability in formulations.
  • Broad acceptance in the pharmaceutical industry.
  • Versatility in applications across food and medicine.

Weaknesses

  • Potential regulatory challenges in various regions.
  • Market volatility due to fluctuations in raw material supply.
  • Competition from other sweeteners and energy sources.

Opportunities

  • Emerging markets in developing countries.
  • Growing health awareness leading to increased demand.
  • Innovation in product formulations enhancing usage.

Threats

  • Stringent regulations and compliance issues.
  • Competitive pressures from alternative sweeteners.
  • Economic downturns affecting the healthcare budget.

Raw Materials Required

  • Corn starch
  • Enzymatic glucose syrup
  • Water

Investment Profiles & Financial Analysis

This project has 4 investment scales. Select a profile to view its figures.

Micro

Capacity: 5 tons/month
Plant Capacity
5 tons/month
Machinery Cost
₹270,000 – ₹330,000
approx. range
Total Investment
₹446,000 – ₹545,000
approx. range
Working Capital (3M)
₹135,000 – ₹165,000
approx. range
Rate of Return
12.00%
Break-Even Point
50.00%
Break-even time: approx. 9 years
Projection quality
Strong projection
Market Demand
Stable
Dextrose monohydrate and liquid glucose have consistent demand in pharmaceuticals and Ayurvedic products, albeit limited scalability.
Risk Level
Medium
Investment is moderate, but competition and operational challenges exist in niche markets, affecting profitability.
Skill Required
Intermediate
Moderate technical knowledge is needed for production, quality control, and regulatory compliance.
Notes:

Feasible for niche local markets but limited growth potential.

Small

Capacity: 20 tons/month
Plant Capacity
20 tons/month
Machinery Cost
₹1,080,000 – ₹1,320,000
approx. range
Total Investment
₹1,782,000 – ₹2,178,000
approx. range
Working Capital (3M)
₹540,000 – ₹660,000
approx. range
Rate of Return
15.00%
Break-Even Point
60.00%
Break-even time: approx. 7 years
Projection quality
Strong projection
Market Demand
Rising
Dextrose monohydrate and liquid glucose are increasingly utilized in pharmaceuticals and Ayurvedic medicines, leading to a growing market demand.
Risk Level
Medium
While the market demand is good, there is competition and operational challenges that may pose moderate risks.
Skill Required
Intermediate
Manufacturing requires a sound understanding of pharmaceutical processes, hence an intermediate skill level is necessary.
Notes:

Good market demand; potential for regional distribution.

Medium

Capacity: 50 tons/month
Plant Capacity
50 tons/month
Machinery Cost
₹2,700,000 – ₹3,300,000
approx. range
Total Investment
₹4,455,000 – ₹5,445,000
approx. range
Working Capital (3M)
₹1,350,000 – ₹1,650,000
approx. range
Rate of Return
18.00%
Break-Even Point
70.00%
Break-even time: approx. 6 years
Projection quality
Strong projection
Market Demand
Rising
There is an increasing demand for dextrose in pharmaceuticals and Ayurvedic medicines due to its multiple applications.
Risk Level
Medium
Moderate competition and regulatory challenges can impact operational stability and investment return timelines.
Skill Required
Intermediate
Technical knowledge in processing and quality control is essential, but not overly complex for skilled operators.
Notes:

Strong market position possible; viable for broader distribution.

Large

Capacity: 100 tons/month
Plant Capacity
100 tons/month
Machinery Cost
₹7,200,000 – ₹8,800,000
approx. range
Total Investment
₹11,880,000 – ₹14,520,000
approx. range
Working Capital (3M)
₹3,600,000 – ₹4,400,000
approx. range
Rate of Return
20.00%
Break-Even Point
75.00%
Break-even time: approx. 5 years
Projection quality
Strong projection
Market Demand
Rising
The increasing use of dextrose in pharmaceuticals and Ayurvedic medicines drives a growing market demand.
Risk Level
Medium
While the market is expanding, competition and regulatory challenges pose moderate risks.
Skill Required
Intermediate
Required knowledge of pharmaceutical production processes necessitates an intermediate skill level.
Notes:

Robust scalability; well-suited for national and export markets.

Frequently Asked Questions

What is this project about?

Dextrose monohydrate, commonly referred to as liquid glucose, is a simple sugar derived from corn or other starch sources. It is primarily used in the pharmaceutical industry, as well as in food and beverage manufacturing, due to its ability to provide quick energy and stabilize formulations. Its versatility allows it to be incorporated into various products, including oral rehydration solutions, intravenous solutions, and nutritional supplements. The compound has a high solubility, making it suitable for both solid and liquid formulations, thereby increasing its applicability. The increasing demand for parenteral nutrition in hospitals and the growing trend of health and wellness products are driving the market for dextrose monohydrate. Additionally, the rise of sports nutrition supplements and functional foods is creating new opportunities for liquid glucose products. Regulatory approvals and quality certifications also underpin its acceptance and usage in various markets globally, enhancing its market presence. Furthermore, dextrose is often used as a sweetening agent and to enhance the palatability of various formulations, contributing to market growth. As consumers shift towards convenient health solutions, the demand for liquid glucose is projected to increase, making it an attractive investment in the pharmaceutical and health sectors.

What is the market potential?

• Rising demand for parenteral nutrition in healthcare settings.
• Increasing use of dextrose in sports and nutrition supplements.
• Growing trend towards functional foods and beverages.
• Expansion of the pharmaceutical sector with intravenous therapies.
• Potential for use in biodegradable packaging and bioengineering.

How much investment is required?

Total capital investment ranges from ₹495,000 to ₹13,200,000 depending on the scale of operation. This covers plant and machinery, civil work, pre-operative expenses, and working capital. Larger scales require proportionally higher investment but typically offer better returns.

When does this project break even?

At the larger investment scale, the expected break-even is approximately approx. 5 years at approximately 75.00% capacity utilisation. Smaller setups may reach break-even sooner due to lower fixed costs relative to the capacity.

What raw materials are required?

• Corn starch
• Enzymatic glucose syrup
• Water

What are the key strengths of this project?

• High solubility and excellent stability in formulations.
• Broad acceptance in the pharmaceutical industry.
• Versatility in applications across food and medicine.

Related topics

dextrose monohydrate